Patent Search Skill
Comprehensive patent analysis for drug discovery and IP intelligence.
Quick Start
code
/patent EGFR inhibitor /fto "quinazoline EGFR kinase" /patent-map KRAS G12C Analyze patent landscape for osimertinib
What's Included
| Section | Description | Data Source |
|---|---|---|
| Patent Search | Find relevant patents | USPTO, EPO, WIPO |
| Patent Details | Claims, assignees, priority | Patent databases |
| FTO Analysis | Freedom to operate assessment | Claims analysis |
| Landscape Map | Patent clustering and gaps | Aggregated |
| Expiration | Patent expiry dates | Patent databases |
| Family Analysis | Patent family members | Global Dossier |
Output Structure
markdown
# Patent Analysis: EGFR Inhibitors ## Executive Summary **Total Patents**: 3,247 EGFR inhibitor patents found **Key Patent Families**: 89 unique families **FTO Risk**: High - crowded landscape with broad claims ## Patent Landscape | Time Period | Patents | Growth | |-------------|---------|--------| | 1990-1999 | 234 | Baseline | | 2000-2009 | 892 | +281% | | 2010-2019 | 1,456 | +63% | | 2020-2024 | 665 | Declining | ## Key Patent Families ### US5747498 (Erlotinib) | Field | Value | |-------|-------| | Assignee | OSI Pharmaceuticals | | Priority Date | 1994-04-15 | | Grant Date | 1998-05-05 | | Expiry | 2018 (expired) | | Claims | 47 claims | | Scope | Quinazoline EGFR inhibitors | ### US8017621 (Gefitinib) | Field | Value | |-------|-------| | Assignee | AstraZeneca | | Priority Date | 1992-03-06 | | Expiry | 2014 (expired) | | Scope | Broad EGFR TKI claims | ## FTO Analysis ### High-Risk Patents | Patent | Risk | Reason | |--------|------|--------| | US8772358 | ⚠️ High | 3rd-gen TKI, C797S active | | US10363010 | ⚠️ High | Broad mutant-selective claims | | US10588034 | ⚠️ High | Combination therapy claims | ### White Space | Area | Opportunity | Rationale | |------|-------------|----------| | 4th-gen TKI | Low IP pressure | C797S+S1278 niche | | Allosteric sites | Emerging | Fewer existing claims | | Bispecific formats | Moderate | Combination IP possible | ## Patent Family Analysis **Example: Osimertinib (AZD9291)** | Jurisdiction | Patent | Status | Expiry | |-------------|--------|--------|--------| | US | US8772358 | Expired | 2033 | | EP | EP2378967 | Granted | 2033 | | JP | JP5958971 | Granted | 2033 | | CN | CN102822420 | Granted | 2033 | ## Claim Analysis **US8772358 Claim 1 (Representative):**
A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disease mediated by EGFR having the T790M mutation...
code
**Breadth:** Broad - covers mutant-selective EGFR inhibitors **Enforceability:** High - well-defined structure **Workaround:** Difficult - covers core scaffold ## Competitive IP Map | Company | Patent Families | Core Focus | |----------|-----------------|-------------| | AstraZeneca | 12 | 3rd-gen TKI, combinations | | Johnson & Johnson | 8 | Bispecific antibodies | | Daiichi Sankyo | 6 | ADC conjugates | | Blueprint Medicines | 4 | 4th-gen TKI | | Yuhan/Roche | 3 | Lazertinib combinations |
Examples
Patent Search
code
/patent EGFR quinazoline /patent-search "KRAS G12C inhibitor" Find all patents for sotorasib
FTO Analysis
code
/fto "EGFR TKI scaffold" /fto-analysis compound.smi Can I make this compound without infringement?
Landscape Mapping
code
/patent-map KRAS inhibitors Map patent landscape for 4th-gen EGFR Analyze IP gaps in PROTAC EGFR degraders
Patent Family
code
/patent US8772358 --family /patent WO2010130291 --global Show all related patents for osimertinib
Running Scripts
bash
# Search patents by keyword python scripts/patent_search.py "EGFR inhibitor" --output patents.json # FTO analysis python scripts/patent_search.py --fto "quinazoline scaffold" --claims # Patent family lookup python scripts/patent_search.py --family US8772358 # Landscape mapping python scripts/patent_search.py --landscape "KRAS G12C" --cluster # Expiration analysis python scripts/patent_search.py --expiry "EGFR TKI" --sort-by-date
Requirements
bash
pip install requests pandas lxml
Additional Resources
Best Practices
- •Start broad: Cast wide net, then filter
- •Check families: Patents span multiple jurisdictions
- •Read claims: Scope determined by claims, not abstract
- •Check expiry: Many drug patents expired
- •Consider licenses: Blocked ≠ impossible (licensing possible)
Common Pitfalls
| Pitfall | Solution |
|---|---|
| Narrow search | Use multiple terms/synonyms |
| Ignoring families | Check global coverage |
| Misreading claims | Claims define scope, not title |
| Overlooked continuations | Check continuation-in-part (CIP) |
| Publication vs. grant | Check granted patent status |